403,304 Shares in Immunocore Holdings plc (NASDAQ:IMCR) Bought by Point72 Asset Management L.P.

Point72 Asset Management L.P. bought a new stake in shares of Immunocore Holdings plc (NASDAQ:IMCR - Free Report) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund bought 403,304 shares of the company's stock, valued at approximately $11,897,000. Point72 Asset Management L.P. owned about 0.81% of Immunocore at the end of the most recent reporting period.

Other hedge funds have also bought and sold shares of the company. Hennion & Walsh Asset Management Inc. boosted its holdings in shares of Immunocore by 125.4% in the 4th quarter. Hennion & Walsh Asset Management Inc. now owns 49,608 shares of the company's stock worth $1,463,000 after purchasing an additional 27,598 shares in the last quarter. Barclays PLC boosted its stake in Immunocore by 2,044.0% in the fourth quarter. Barclays PLC now owns 20,625 shares of the company's stock worth $608,000 after buying an additional 19,663 shares in the last quarter. Crossmark Global Holdings Inc. grew its position in Immunocore by 36.7% during the fourth quarter. Crossmark Global Holdings Inc. now owns 38,020 shares of the company's stock valued at $1,121,000 after acquiring an additional 10,217 shares during the last quarter. Legal & General Group Plc grew its position in Immunocore by 17.3% during the fourth quarter. Legal & General Group Plc now owns 136,875 shares of the company's stock valued at $4,038,000 after acquiring an additional 20,163 shares during the last quarter. Finally, Primecap Management Co. CA raised its stake in shares of Immunocore by 8.0% during the fourth quarter. Primecap Management Co. CA now owns 2,668,550 shares of the company's stock worth $78,722,000 after acquiring an additional 196,530 shares in the last quarter. 84.50% of the stock is currently owned by institutional investors.

Immunocore Trading Down 0.7%

Shares of NASDAQ IMCR traded down $0.21 during trading hours on Friday, hitting $31.01. The company's stock had a trading volume of 43,587 shares, compared to its average volume of 410,553. Immunocore Holdings plc has a 12 month low of $23.15 and a 12 month high of $50.50. The stock has a market cap of $1.55 billion, a price-to-earnings ratio of -32.64 and a beta of 0.75. The company has a debt-to-equity ratio of 1.03, a quick ratio of 3.76 and a current ratio of 3.78. The business has a 50-day simple moving average of $28.95 and a 200-day simple moving average of $30.05.

Immunocore (NASDAQ:IMCR - Get Free Report) last released its quarterly earnings data on Wednesday, May 7th. The company reported $0.10 earnings per share for the quarter, topping the consensus estimate of ($0.35) by $0.45. Immunocore had a negative return on equity of 12.84% and a negative net margin of 15.87%. The business had revenue of $125.13 million during the quarter, compared to analysts' expectations of $108.82 million. During the same quarter last year, the business posted ($0.49) EPS. The business's revenue was up 33.6% on a year-over-year basis. On average, analysts anticipate that Immunocore Holdings plc will post -0.94 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on IMCR. Morgan Stanley reaffirmed an "equal weight" rating and issued a $35.00 price objective on shares of Immunocore in a research note on Friday, March 7th. Needham & Company LLC reaffirmed a "buy" rating and set a $71.00 price objective on shares of Immunocore in a research note on Thursday, April 10th. Mizuho decreased their price objective on Immunocore from $38.00 to $33.00 and set a "neutral" rating on the stock in a report on Monday, April 7th. Oppenheimer increased their target price on Immunocore from $85.00 to $86.00 and gave the company an "outperform" rating in a report on Thursday, May 8th. Finally, HC Wainwright restated a "buy" rating and set a $100.00 price target on shares of Immunocore in a research report on Wednesday, March 12th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and six have given a buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $58.13.

Insider Buying and Selling

In related news, Director Bros. Advisors Lp Baker purchased 807,338 shares of the firm's stock in a transaction that occurred on Monday, March 17th. The stock was bought at an average cost of $29.72 per share, with a total value of $23,994,085.36. Following the completion of the purchase, the director now directly owns 2,144,060 shares in the company, valued at approximately $63,721,463.20. This represents a 60.40% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 10.40% of the stock is currently owned by insiders.

Immunocore Company Profile

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.